Enanta (ENTA) awards 20,000 stock options to director Yujiro S. Hata

Rhea-AI Filing Summary

Enanta Pharmaceuticals director Yujiro S. Hata received a grant of stock options for 20,000 shares of common stock. The options have a $14.17 exercise price, were granted on March 11, 2026, and expire on March 11, 2036.

The options will vest in substantially equal monthly installments over one year starting from the March 11, 2026 grant date, with the final monthly installment vesting no later than the nearest Nasdaq Global Select Market trading day before the 2027 annual stockholders meeting. Following this grant, Hata holds 20,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hata Yujiro S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 20,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hata Yujiro S

(Last) (First) (Middle)

C/O ENANTA PHARMACEUTICALS, INC.

4 KINGSBURY AVENUE

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS INC [ ENTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.17	03/11/2026		A		20,000		(1)	03/11/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.

	/s/ Matthew Kowalsky as attorney-in-fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Enanta (ENTA) director Yujiro S. Hata report on this Form 4?

Yujiro S. Hata reported receiving a grant of stock options for 20,000 shares of Enanta common stock. These options are a compensation-related award, not an open-market share purchase or sale, and give him the right to buy shares at a fixed exercise price.

How many Enanta (ENTA) stock options were granted and at what exercise price?

The filing shows a grant of stock options covering 20,000 shares of Enanta common stock at a $14.17 exercise price. This means Hata can later purchase those shares at $14.17 per share if he exercises the options after they vest.

When do Yujiro S. Hata’s Enanta (ENTA) stock options vest?

The options vest monthly in substantially equal installments over one year starting from the March 11, 2026 grant date. The final monthly installment will vest no later than the nearest Nasdaq Global Select Market trading day before Enanta’s 2027 annual meeting of stockholders.

When do the Enanta (ENTA) stock options granted to Hata expire?

The stock options granted to Yujiro S. Hata expire on March 11, 2036. After that expiration date, any unexercised portion of the 20,000-share option grant can no longer be used to purchase Enanta common stock at the $14.17 exercise price.

Is this Enanta (ENTA) Form 4 a market transaction or a compensation grant?

This Form 4 reflects a compensation grant, not an open-market trade. The transaction code “A” denotes a grant or award acquisition of stock options, giving Hata the right to buy 20,000 Enanta shares at $14.17, subject to the stated vesting schedule and expiration date.

What is Yujiro S. Hata’s position in Enanta (ENTA) options after this grant?

After the reported grant, Hata directly holds stock options covering 20,000 shares of Enanta common stock. The filing does not list additional derivative positions, so this 20,000-share option award represents his reported derivative holding following the March 11, 2026 compensation grant.